Keyword: Antibody-Drug Conjugates (ADC)
Chemistry & Life Sciences
13.05.2022
-
Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.
Strategy & Management
16.09.2021
-
Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...
News
15.09.2020
-
US-based CDMO Catalent is joining forces with compatriot drug discovery company Exelixis to develop multiple antibody-drug conjugates (ADCs). The company’s Redwood...
Chemistry & Life Sciences
10.09.2020
-
For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.
News
26.09.2017
- ADC Biotechnology (ADC Bio) has secured investment for the construction of an $11 million bioconjugation facility at its new site in Deeside, North Wales, UK. A substantial part of...
News
12.06.2017
- UK biotech Glythera has launched a project to develop next-generation antibody drug conjugates (ADCs) for difficult-to-treat tumors, backed by funding of £1 million from government...
Research & Innovation
06.12.2016
- Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs...
News
13.10.2016
- CMC Biologics and IDT Biologika announced the addition of Cerbios and Oncotec Pharma to PROVEO, their strategic collaboration for providing a complete and efficient solution to the...
